Catalog
Khavinson tripeptide (Glu-Asp-Arg)
Pinealon
Even thinner literature than Epitalon — almost entirely cell-culture and rodent from one group.
Research-only / unregulatedGrade F — Misleading or falseFDA Category 2 (2023) — barred from 503A compounding
Target
Putative neuroprotective / pineal pathway
Mechanism of action
Proposed neuroprotective tripeptide. Evidence is preclinical from the Khavinson institute. No mechanistic confirmation in humans.
Pharmacokinetics
Intranasal/SC in unregulated use.
Clinical context
None FDA-approved.
Safety
Contraindications
- Pregnancy
Adverse effects
- Unknown — no human pharmacovigilance
Covered in modules
Module 13
Cognitive & Nootropic Peptides
Semax, Selank, Cerebrolysin, Dihexa, Cerebrolysin, NSI-189-style claims.
Module 15
Controversies, Pipeline & Frontier
What's in phase II/III right now — and what 2027 will probably look like.
Module 16
Khavinson 'Bioregulator' Peptides — Deep Dive
40+ years of Russian research, one institution, almost no independent replication. What clinicians actually need to know about Epitalon, Pinealon, Vesugen, Vilon, and Cortexin.
Related compounds
Generate prescriber-grade deep dive
Pull in expanded mechanism, PK/PD, dosing strategies for special populations, drug interactions, monitoring cadence, head-to-head differentials, prescriber pearls, and patient FAQs for Pinealon.
Educational reference. Not medical advice. Always verify against current FDA labeling and local regulatory guidance before prescribing or counseling.